G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $45.66, for a total transaction of $34,245.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Shares of G1 Therapeutics stock opened at $45.94 on Friday. G1 Therapeutics Inc has a 12 month low of $12.04 and a 12 month high of $52.76.
G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Thursday, May 3rd. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.07). equities analysts forecast that G1 Therapeutics Inc will post -2.75 EPS for the current year.
A number of research firms have weighed in on GTHX. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. HC Wainwright started coverage on shares of G1 Therapeutics in a report on Tuesday, May 29th. They issued a “buy” rating and a $61.00 target price on the stock. Needham & Company LLC lifted their target price on shares of G1 Therapeutics from $42.00 to $60.00 and gave the company a “buy” rating in a report on Friday, May 18th. Finally, Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.00.
Several institutional investors have recently made changes to their positions in GTHX. Swiss National Bank acquired a new position in shares of G1 Therapeutics in the 4th quarter valued at $286,000. Bank of New York Mellon Corp increased its holdings in shares of G1 Therapeutics by 28.4% in the 4th quarter. Bank of New York Mellon Corp now owns 29,341 shares of the company’s stock valued at $582,000 after acquiring an additional 6,483 shares during the period. BlackRock Inc. increased its stake in G1 Therapeutics by 113.5% in the 4th quarter. BlackRock Inc. now owns 745,445 shares of the company’s stock valued at $14,790,000 after buying an additional 396,215 shares during the period. Geode Capital Management LLC increased its stake in G1 Therapeutics by 9.3% in the 4th quarter. Geode Capital Management LLC now owns 94,366 shares of the company’s stock valued at $1,872,000 after buying an additional 8,061 shares during the period. Finally, Franklin Resources Inc. increased its stake in G1 Therapeutics by 10.1% in the 4th quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after buying an additional 141,000 shares during the period. 61.04% of the stock is currently owned by institutional investors and hedge funds.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.